Patents by Inventor Chenxi Shen

Chenxi Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEIN OF RELAXIN OR ANALOGUE AND MEDICAL USE THEREOF
    Publication number: 20250312444
    Abstract: The present disclosure relates to a fusion protein of relaxin or an analogue and the medical use thereof. Specifically, the present disclosure relates to a fusion protein comprising relaxin or an analogue thereof and a serum albumin binding domain, and the medical use thereof for treating diseases (for example, heart failure). Moreover, the present disclosure relates to a serum albumin binding molecule, which comprises an immunoglobulin single variable domain (for example, VHH) capable of binding to serum albumin, has good plasma stability, and can be used for prolonging the plasma half-life of a drug.
    Type: Application
    Filed: May 5, 2023
    Publication date: October 9, 2025
    Inventors: Yanping Du, Lei Wang, Xiao Liu, Hong Gao, Chenxi Shen, Linshuang Zhang, Peng Jiang
  • HUMAN INSULIN ANALOGUE, AND FUSION PROTEIN THEREOF AND MEDICAL USE THEREOF
    Publication number: 20250206797
    Abstract: A human insulin analogue, and a fusion protein thereof and the medical use thereof. The human insulin analogue-Fc fusion protein has ultra-long in-vivo pharmacokinetic properties and can be used for treating metabolic diseases (such as type-I diabetes and type-II diabetes).
    Type: Application
    Filed: March 16, 2023
    Publication date: June 26, 2025
    Inventors: Fangzhou WU, Peng JIANG, Chenxi SHEN, Yanping DU, Renzhi LIU, Yuanyuan LI, Xuchao HUANG, Xugang HE, Lei WANG
  • ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230220111
    Abstract: Provided are an anti-FXI/FXIa antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof, as well as a pharmaceutical composition comprising the anti-FXI/FXIa antibody or the antigen-binding fragment thereof, and a method for treating and preventing a disease, in particular a method for treating thrombosis or thromboembolism-related diseases or disorders.
    Type: Application
    Filed: July 2, 2021
    Publication date: July 13, 2023
    Inventors: Lei WANG, Xugang HE, Jin ZHANG, Xiao LIU, Dongmei HU, Yanping DU, Ran WU, Chenxi SHEN, Yang YANG, Changyong YANG
  • Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins
    Patent number: 9862746
    Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 9, 2018
    Assignee: The Regents of the University of Michigan
    Inventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess
  • COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS
    Publication number: 20150368300
    Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 24, 2015
    Inventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess